MARKET

NBY

NBY

NOVABAY PHARMA
AMEX

Real-time Quotes | Nasdaq Last Sale

0.6350
+0.0150
+2.42%
After Hours: 0.6270 -0.008 -1.26% 19:30 11/25 EST
OPEN
0.6250
PREV CLOSE
0.6200
HIGH
0.6413
LOW
0.6130
VOLUME
505.25K
TURNOVER
--
52 WEEK HIGH
1.940
52 WEEK LOW
0.2400
MARKET CAP
26.53M
P/E (TTM)
-1.5473
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
NovaBay Pharma rises 8% on Avenova distribution deal in Australia
NovaBay Pharmaceuticals (NBY) perks 8% premarket after signing an agreement with Paragon Care Group Australia Pty Ltd for the exclusive distribution of Avenova in Australia.Paragon Care Group will begin distributing Avenova directly to consumers under
Seekingalpha · 3d ago
NovaBay Pharmaceuticals Expands Avenova's Geographic Reach to Australia with New Exclusive Distribution Agreement
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a pharmaceutical company focusing on commercializing Avenova® for the eye care market, announces the signing of an agreement with Paragon Care Group Australia Pty Ltd
Benzinga · 3d ago
President-Elect Biden Says Discussed Nationwide Mask Mandate With State Governors
-Reuters-Reuters
Reuters-Reuters · 6d ago
NovaBay Pharmaceuticals Q3 EPS $(0.08) Misses $(0.04) Estimate, Sales $2.17M Miss $2.52M Estimate
NovaBay Pharmaceuticals (AMEX:NBY) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.04) by 100 percent. This is a 300 percent decrease over losses of $(0.02) per share
Benzinga · 11/12 21:23
NovaBay EPS misses by $0.04, misses on revenue
NovaBay (NBY): Q3 GAAP EPS of -$0.08 misses by $0.04.Revenue of $2.17M (+34.0% Y/Y) misses by $0.35M.Shares -1.4%.Press Release
Seekingalpha · 11/12 21:10
NovaBay Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / NovaBay Pharmaceuticals, Inc.
ACCESSWIRE · 11/12 19:30
NovaBay Announces Consumer Launch of CelleRx® Clinical Reset™
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) announces the consumer launch of Clinical Reset, an FDA-cleared skincare product proven to help clean and reduce the buildup of bacteria on facial skin. A patented spray solution,
Benzinga · 11/12 11:55
BZ NOTE: FDA.gov Website Shows Warning Letter Dated Nov. 2 Related To NovaBay's Avenova; Shares Down 7%
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novabay-pharmaceuticals-inc-610816-11022020
Benzinga · 11/03 17:41
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NBY. Analyze the recent business situations of NOVABAY PHARMA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NBY stock price target is 2.625 with a high estimate of 3.500 and a low estimate of 1.750.
EPS
Institutional Holdings
Institutions: 20
Institutional Holdings: 647.60K
% Owned: 1.55%
Shares Outstanding: 41.78M
TypeInstitutionsShares
Increased
3
383.59K
New
7
174.48K
Decreased
6
97.70K
Sold Out
2
12.42K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
President/Chief Executive Officer/Director
Justin Hall
Chief Financial Officer/Treasurer
Andrew Jones
Director
Xinzhou Li
Director
Mijia Wu
Independent Director
Paul Freiman
Independent Director
Swan Sit
Independent Director
Yenyou Zheng
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NBY
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of NovaBay Pharmaceuticals, Inc. stock information, including AMEX:NBY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBY stock methods without spending real money on the virtual paper trading platform.